Jan 20 2010
Simbionix, the world's
leading developer of medical simulation systems, introduces its new module
for the ANGIO Mentor simulator, the Percutaneous Aortic Valve Replacement
Module, which provides physicians with an opportunity to practice a
revolutionary endovascular implantation of a bioprosthesis, without
performing cardiac surgery.
Percutaneous aortic valve replacement is an innovative minimally invasive
technique for heart valve implantation. This procedure, which takes place in
a catheterization lab, is performed on a beating heart, so that there is no
need for a cardiopulmonary bypass and its associated risks. In addition to
having the potential to treat and heal many of the patients who are
ineligible for traditional open-heart surgery, including elderly patients or
patients suffering from additional conditions, this new technique is also
less traumatic to the patient, and reduces healthcare costs and
rehabilitation time.
The new training module provides surgeons with the opportunity to
practice correct placement of the bioprosthesis during an Aortic Valve
Replacement, which is critical for the success of the procedure. Surgeons can
train on different virtual patients, and gain experience with complicated
anatomies and various pathologies. At the end of the session the surgeon can
assess and analyze the deployment process and learn how to work more safely
with a bioprosthesis.
Mr. Gary Zamler, Simbionix CEO adds: "The medical device field is rapidly
developing, with new technologies continuously being introduced to the market
and new techniques being used every day. Based on the work of our
exceptionally strong R&D team, we are able to assist clinicians in keeping up
with these changes, while at the same time contributing to enhanced patient
safety. Device manufactures share the same needs, and require advanced and
efficient training tools. Simbionix solutions provide a wide scope of
opportunities to attend to this positive trend in medical device
developments, an example of which is demonstrated in this new application for
percutaneous aortic valve replacement".
SOURCE Simbionix Ltd.